Can a patient with a history of deep‑vein thrombosis be treated for varicose veins with endovenous thermal ablation and Varithena (polidocanol) foam sclerotherapy?

Treatment of Varicose Veins with Ablation and Varithena in Patients with Prior DVT

Direct Answer

Yes, you can treat varicose veins with both endovenous thermal ablation and Varithena (polidocanol foam) in patients with a history of deep vein thrombosis, but these patients face a moderately elevated risk of recurrent DVT (1.4% vs 0.8% in patients without DVT history) and require careful counseling about this risk. 1

---

Risk Stratification for Prior DVT Patients

Documented Thrombotic Risk with Thermal Ablation

• Patients with prior DVT have nearly double the risk of new DVT after endovenous thermal ablation (1.4%) compared to those without DVT history (0.8%), though the absolute risk remains low. 1

• The risk of proximal thrombus extension is also elevated in prior DVT patients (2.3% vs 1.6%). 1

• Importantly, pulmonary embolism risk and EHIT II-IV rates do not differ significantly between patients with and without DVT history. 1

• No procedural deaths occurred in either group in a large registry study of over 33,000 thermal ablations. 1

Documented Thrombotic Risk with Varithena

• The FDA label explicitly warns that patients with history of DVT are at increased risk for developing thrombosis after Varithena treatment. 2

• In clinical trials, DVT occurred in 4.7% of Varithena-treated patients versus 0% in placebo groups. 2

• One recent randomized trial reported DVT rates as high as 14.7-16.7% after Varithena when using only compression, though this may reflect more extensive treatment territories. 3

---

Treatment Algorithm for Prior DVT Patients

Step 1: Confirm Deep Venous Patency

• Perform duplex ultrasound to document that the deep venous system is patent before proceeding with any superficial venous ablation. 2

• Patients with underlying arterial disease (marked peripheral arteriosclerosis or thromboangiitis obliterans) are at increased risk for tissue ischemia and may not be suitable candidates. 2

Step 2: Choose Ablation Modality

• Endovenous thermal ablation (laser or radiofrequency) remains first-line therapy for symptomatic varicose veins with documented reflux, even in patients with prior DVT. 4

• Varithena polidocanol foam is recommended as second-line therapy, particularly useful for recurrent varicose veins after prior surgery or for below-knee saphenous reflux where it avoids the 7% nerve injury risk associated with thermal ablation. 4

• Both thermal ablation and Varithena demonstrate comparable long-term closure rates (thermal ablation 91-100% at 1 year; Varithena not statistically different from thermal ablation in network meta-analysis). 5, 6

Step 3: Implement Risk-Reduction Strategies

For Thermal Ablation:

• The decision to continue or withhold anticoagulation preoperatively should be made case-by-case, as continuing anticoagulation does not change complication rates but does increase hematoma risk. 1

For Varithena:

• Consider 5 days of postprocedural apixaban 5 mg twice daily, which reduced DVT occurrence from 16.7% to 1.98% in a randomized trial—comparable to thermal ablation DVT rates. 3

• Implement adjunctive intraoperative techniques: limb elevation >45°, ultrasound mapping and digital occlusion of large perforators, limitation of foam volume per session, saline injection before treatment, and compression in the elevated position. 7

• These adjunctive techniques reduced thrombus extension into deep veins to 1.5% in one series, significantly lower than the 16.1% infusion site thrombosis rate reported in FDA trials. 7, 2

Step 4: Post-Procedure Monitoring

• Observe all patients for at least 10 minutes following Varithena injection to monitor for anaphylaxis. 2

• Perform duplex ultrasound 7-10 days post-procedure to assess for DVT or thrombus extension. 3, 7

• Note that D-dimer is commonly elevated post-treatment with Varithena and is not useful diagnostically for assessing venous thrombus. 2

---

Critical Counseling Points

Efficacy Remains Intact

• Despite elevated thrombotic risk, technical success and recanalization rates at early follow-up are similar between patients with and without DVT history (2.0% vs 1.2% technical failure). 1

• However, prior DVT does confer increased recanalization risk over time (hazard ratio 1.90). 1

• Quality-of-life improvements (Venous Clinical Severity Score and HASTI scores) are comparable regardless of DVT history. 1

Absolute vs Relative Risk

• While the relative risk of DVT is nearly doubled in prior DVT patients, the absolute risk increase is only 0.6% (from 0.8% to 1.4%) with thermal ablation. 1

• This modest absolute increase must be weighed against the proven efficacy and quality-of-life benefits of treating symptomatic venous insufficiency. 1

---

Common Pitfalls to Avoid

• Do not reflexively withhold anticoagulation in all prior DVT patients undergoing thermal ablation—this decision requires individualized assessment as continuation does not reduce thrombotic complications but does increase bleeding risk. 1

• Do not use Varithena without implementing adjunctive risk-reduction techniques (limb elevation, perforator occlusion, compression) in high-risk patients, as this significantly impacts DVT rates. 7

• Do not rely on D-dimer testing post-Varithena to rule out DVT—duplex ultrasound is required. 2

• Do not forget that patients with reduced mobility, recent major surgery (within 3 months), prolonged hospitalization, or pregnancy are at even higher baseline risk for thrombosis and require heightened vigilance. 2